227 related articles for article (PubMed ID: 25469095)
1. Radiofrequency ablation to treat loco-regional recurrence of well-differentiated thyroid carcinoma.
Lee SJ; Jung SL; Kim BS; Ahn KJ; Choi HS; Lim DJ; Kim MH; Bae JS; Kim MS; Jung CK; Chong SM
Korean J Radiol; 2014; 15(6):817-26. PubMed ID: 25469095
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of radiofrequency ablation for treating locoregional recurrence from papillary thyroid cancer.
Lim HK; Baek JH; Lee JH; Kim WB; Kim TY; Shong YK; Hong SJ
Eur Radiol; 2015 Jan; 25(1):163-70. PubMed ID: 25199815
[TBL] [Abstract][Full Text] [Related]
3. mRECIST criteria to assess recurrent thyroid carcinoma treatment response after radiofrequency ablation: a prospective study.
Mazzeo S; Cervelli R; Elisei R; Tarantini G; Cappelli C; Molinaro E; Galleri D; De Napoli L; Comite C; Cioni R; Vitti P; Caramella D
J Endocrinol Invest; 2018 Dec; 41(12):1389-1399. PubMed ID: 29687416
[TBL] [Abstract][Full Text] [Related]
4. Radiofrequency ablation and percutaneous ethanol injection treatment for recurrent local and distant well-differentiated thyroid carcinoma.
Monchik JM; Donatini G; Iannuccilli J; Dupuy DE
Ann Surg; 2006 Aug; 244(2):296-304. PubMed ID: 16858194
[TBL] [Abstract][Full Text] [Related]
5. Locoregional control of metastatic well-differentiated thyroid cancer by ultrasound-guided radiofrequency ablation.
Baek JH; Kim YS; Sung JY; Choi H; Lee JH
AJR Am J Roentgenol; 2011 Aug; 197(2):W331-6. PubMed ID: 21785061
[TBL] [Abstract][Full Text] [Related]
6. Long-term results of radiofrequency ablation for locally recurrent papillary thyroid carcinoma.
Yang Z; Yan L; Xiao J; Li W; Li X; Li Y; Zhang M; Luo Y
Int J Hyperthermia; 2023; 40(1):2191912. PubMed ID: 37164353
[TBL] [Abstract][Full Text] [Related]
7. Ultrasonography-guided percutaneous radiofrequency ablation for cervical lymph node metastasis from thyroid carcinoma.
Wang L; Ge M; Xu D; Chen L; Qian C; Shi K; Liu J; Chen Y
J Cancer Res Ther; 2014 Nov; 10 Suppl():C144-9. PubMed ID: 25450273
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of percutaneous ultrasound guided radiofrequency ablation for treating cervical metastatic lymph nodes from papillary thyroid carcinoma.
Guang Y; Luo Y; Zhang Y; Zhang M; Li N; Zhang Y; Tang J
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1555-1562. PubMed ID: 28342000
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Follow-Up Results of Ultrasound-Guided Radiofrequency Ablation for Low-Risk Papillary Thyroid Microcarcinoma: More Than 5-Year Follow-Up for 84 Tumors.
Cho SJ; Baek SM; Lim HK; Lee KD; Son JM; Baek JH
Thyroid; 2020 Dec; 30(12):1745-1751. PubMed ID: 32375570
[No Abstract] [Full Text] [Related]
10. Efficacy and Safety of Ultrasound-Guided Radiofrequency Ablation for Treating Low-Risk Papillary Thyroid Microcarcinoma: A Prospective Study.
Zhang M; Luo Y; Zhang Y; Tang J
Thyroid; 2016 Nov; 26(11):1581-1587. PubMed ID: 27445090
[TBL] [Abstract][Full Text] [Related]
11. US-Guided Radiofrequency Ablation for Low-Risk Papillary Thyroid Microcarcinoma: Efficacy and Safety in a Large Population.
Lim HK; Cho SJ; Baek JH; Lee KD; Son CW; Son JM; Baek SM
Korean J Radiol; 2019 Dec; 20(12):1653-1661. PubMed ID: 31854153
[TBL] [Abstract][Full Text] [Related]
12. Longer-term outcomes of radiofrequency ablation for locally recurrent papillary thyroid cancer.
Chung SR; Baek JH; Choi YJ; Lee JH
Eur Radiol; 2019 Sep; 29(9):4897-4903. PubMed ID: 30805701
[TBL] [Abstract][Full Text] [Related]
13. Ultrasound-Guided Radiofrequency Ablation of Locally Recurrent Thyroid Carcinoma.
Chegeni H; Ebrahiminik H; Mosadegh Khah A; Malekzadeh H; Abbasi M; Molooghi K; Fadaee N; Kargar J
Cardiovasc Intervent Radiol; 2022 May; 45(5):677-684. PubMed ID: 35066613
[TBL] [Abstract][Full Text] [Related]
14. Locoregional control of recurrent papillary thyroid carcinoma by ultrasound-guided percutaneous microwave ablation: A prospective study.
Yue W; Chen L; Wang S; Yu S
Int J Hyperthermia; 2015 Jun; 31(4):403-8. PubMed ID: 25792224
[TBL] [Abstract][Full Text] [Related]
15. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?
Bannas P; Derlin T; Groth M; Apostolova I; Adam G; Mester J; Klutmann S
Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540
[TBL] [Abstract][Full Text] [Related]
16. Treatment Efficacy of Radiofrequency Ablation for Recurrent Tumor at the Central Compartment After Hemithyroidectomy.
Chung SR; Baek JH; Choi YJ; Sung TY; Song DE; Kim TY; Lee JH
AJR Am J Roentgenol; 2021 Jun; 216(6):1574-1578. PubMed ID: 33787293
[No Abstract] [Full Text] [Related]
17. Pre-ablation stimulated thyroglobulin is a better predictor of recurrence in pathological N1a papillary thyroid carcinoma than the lymph node ratio.
Chang YW; Kim HS; Jung SP; Kim HY; Lee JB; Bae JW; Son GS
Int J Clin Oncol; 2016 Oct; 21(5):862-868. PubMed ID: 26837274
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Radiofrequency and Ethanol Ablation for Treating Locally Recurrent Thyroid Cancer: A Systematic Review and Meta-Analysis.
Suh CH; Baek JH; Choi YJ; Lee JH
Thyroid; 2016 Mar; 26(3):420-8. PubMed ID: 26782174
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of radiofrequency ablation for treating the local recurrence of thyroid cancers.
Zhao Q; Tian G; Kong D; Jiang T
J Endocrinol Invest; 2016 Aug; 39(8):909-16. PubMed ID: 26980591
[TBL] [Abstract][Full Text] [Related]
20. Cancer-free survival and local tumor control after impendence-based radiofrequency ablation of biopsy-proven renal cell carcinomas with a minimum of 1-year follow-up.
Forauer AR; Dewey BJ; Seigne JD
Urol Oncol; 2014 Aug; 32(6):869-76. PubMed ID: 24946958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
